• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
Transcription Factors / Related Products
You are here: Product Lines > DNA Regulation / Transcription > Transcription Factors / Related Products
 
Toolbar - View Selection
 
 Items 50-100 of 195 Page 2 of 4 Select Page: << 1 2 3 4  >>  
ALX-350-260 Revised 11-Aug-08
Lactacystin (synthetic)
Add to Clipboard
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Antibiotics - Proteasome / Ubiquitin Modulators
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-260-MC01   0.1 mg 95.00 USD Add To Cart
ALX-350-260-M001   1 mg 730.00 USD Add To Cart
Product Specification
FORMULA: C15H24N2O7S
MW: 376.4
CAS NUMBER: 133343-34-7
SOURCE/HOST: Synthetic.
PURITY: ≥98% (HPLC)
APPEARANCE: White to off-white powder.
SOLUBILITY: Soluble in acetonitrile (20mg/ml), 100% ethanol (1mg/ml), methanol, DMSO (20mg/ml), dimethyl formamide (20mg/ml) or water (5mg/ml).
ACTIVITY: kobs/[I]=4’000M-1sec-1 versus 20S:PA28 complex.
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
USE/STABILITY: Organic stock solutions are stable for 3 months when stored at -20°C. Subject to hydrolysis in aqueous buffers. We do not recommend storing aqueous solutions for more than one day.
HANDLING: Protect from light. Avoid freeze/thaw cycles.
IDENTITY: Identity determined by 1H-NMR.

Product Description
Cell permeable and irreversible proteasome inhibitor. Specifically inhibits 26S proteasome (MCP; multicatalytic proteinase complex). Blocks proteasome activity by targeting the catalytic β-subunit. Has no effect on serine or cysteine proteases. Induces apoptosis in human monoblast U937 cells. Also inhibits NF-κB activation by inhibiting IκB degradation. Inhibits the ubiquitin proteasome pathway in cell culture (IC50=10µM).  Inhibits cathepsin A . Upregulates HSP70 and HSP22, suggesting an initial neuroprotective pathway.
Product Specific Literature References
Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells: S. Omura, et al.; J. Antibiot. 44, 113 (1991) Abstract
A beta-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line: G. Fenteany, et al.; PNAS 91, 3358 (1994) Abstract
Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells: S. Imajo-Ohmi, et al.; BBRC 217, 1070 (1995) Abstract
The neuritogenesis inducer lactacystin arrests cell cycle at both G0/G1 and G2 phases in neuro 2a cells: M. Katagiri, et al.; J. Antibiot. (Tokyo) 48, 344 (1995) Abstract
Degradation process of ligand-stimulated platelet-derived growth factor beta-receptor involves ubiquitin-proteasome proteolytic pathway: S. Mori, et al.; J. Biol. Chem. 270, 29447 (1995) Abstract; Full Text
Structure-activity relationships of lactacystin, the first non-protein neurotrophic factor: T. Nagamitsu, et al.; J. Antibiotics 48, 747 (1995) Abstract
Neuronal differentiation of Neuro 2a cells by lactacystin and its partial inhibition by the protein phosphatase inhibitors calyculin A and okadaic acid: H. Tanaka, et al.; BBRC 216, 291 (1995) Abstract
Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin: G. Fenteany, et al.; Science 268, 726 (1995) Abstract
Proteasome-dependent regulation of p21WAF1/CIP1 expression: M.V. Blagosklonny, et al.; BBRC 227, 564 (1996) Abstract
Enhancement of CPP32-like activity in the TNF-treated U937 cells by the proteasome inhibitors: E. Fujita, et al.; BBRC 224, 74 (1996) Abstract
Degradation of 3-hydroxy-3-methylglutaryl-CoA reductase in endoplasmic reticulum membranes is accelerated as a result of increased susceptibility to proteolysis: T.P. McGee, et al.; J.Biol. Chem. 271, 25630 (1996) Abstract; Full Text
Lactacystin increases LDL receptor level on HepG2 cells: H. Miura, et al.; BBRC 227, 684 (1996) Abstract
Proteasome pathway operates for the degradation of ornithine decarboxylase in intact cells: Y. Murakami, et al.; Biochem. J. 317, 77 (1996) Abstract
Lactacystin, an inhibitor of the proteasome, blocks the degradation of a mutant precursor of glycosylphosphatidylinositol-linked protein in a pre-Golgi compartment: K. Oda, et al.; BBRC 219, 800 (1996) Abstract
Degradation of a mutant secretory protein, alpha1-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity: D. Qu, et al.; J. Biol. Chem. 271, 22791 (1996) Abstract; Full Text
Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway: H. Yoshida, et al.; Cancer Res. 56, 2945 (1996) Abstract
Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation: A. Craiu, et al.; J. Biol. Chem. 272, 13437 (1997) Abstract; Full Text
The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis: J. Delic, et al.; Br. J. Cancer 77, 1103 (1998) Abstract
Lactacystin, proteasome function, and cell fate: G. Fenteany & S.L. Schreiber; J. Biol. Chem. 273, 8545 (1998), (Review) Abstract; Full Text
The role of proteolysis during differentiation of Trypanosoma brucei from the bloodstream to the procyclic form: M.C. Mutomba, et al.; Mol. Biochem. Parasitol. 93, 11 (1998) Abstract
Proteasome inhibitors prevent the degradation of familial Alzheimer's disease-linked presenilin 1 and potentiate A beta 42 recovery from human cells: P. Marambaud, et al.; Mol. Med. 4, 147 (1998) Abstract
Proteasome inhibitors MG132 and lactacystin hyperphosphorylate HSF1 and induce hsp70 and hsp27 expression: D. Kim, et al.; BBRC 254, 264 (1999) Abstract
Proteasome inhibitors induce mitochondria-independent apoptosis in human glioma cells: H. Kitagawa, et al.; FEBS Lett. 443, 181 (1999) Abstract
Lactacystin, a specific inhibitor of the proteasome, induces apoptosis and activates caspase-3 in cultured cerebellar granule cells: L.A. Pasquini, et al.; J. Neurosci. Res. 59, 601 (2000) Abstract
Proteasome inhibitors induce cytochrome c-caspase-3-like protease- mediated apoptosis in cultured cortical neurons: J.H. Qiu, et al.; J. Neurosci. 20, 259 (2000) Abstract
Lactacystin activates FLICE (caspase 8) protease and induces apoptosis in Fas-resistant adult T-cell leukemia cell lines: Y. Yamada, et al.; Eur. J. Haematol. 64, 315 (2000) Abstract
Lactacystin, a proteasome inhibitor: discovery and its application in cell biology: H. Tomoda & S. Omura; Yakugaku Zasshi 120, 935 (2000), Review Abstract
Lactacystin inhibits cathepsin A activity in melanoma cell lines: L. Kozlowski, et al.; Tumour Biol. 22, 211 (2001) Abstract
Proteasome inhibition by lactacystin in primary neuronal cells induces both potentially neuroprotective and pro-apoptotic transcriptional responses: a microarray analysis: E.H. Yew, et al.; J. Neurochem. 94, 943 (2005) Abstract
Further Categories Containing This Product:
Proteasome / Related Products • Antitumor Antibiotics • Antibiotics for Angiogenesis Research • Antibiotics - NF-kB Inhibitors • NF-kB Pathway Inhibitors • Antibiotics - Apoptosis Inducers & Inhibitors
 
 
ALX-430-095 Revised 23-Jan-08
Leflunomide
Add to Clipboard
SYNONYMS HWA486
5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide)
N-(4-Trifluoromethylphenyl)-5-methylisoxazol-4-carboxamide
PRODUCT LINE Immunology
PRODUCT CATEGORY Immunomodulators Other Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-430-095-M010   10 mg 15.00 USD Add To Cart
ALX-430-095-M050   50 mg 40.00 USD Add To Cart
ALX-430-095-G001   1 g 380.00 USD Add To Cart
Product Specification
FORMULA: C12H9F3N2O2
MW: 270.2
CAS NUMBER: 75706-12-6
MERCK INDEX: 14: 5432
RTECS: NY2354200
PURITY: ≥99% (HPLC)
APPEARANCE: White to off-white solid.
SOLUBILITY: Soluble in DMSO or methanol.
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C
HANDLING: Keep under inert gas. Protect from light.
HAZARD: HARMFUL.

Product Description
Immunosuppressive drug that inhibits T and B cell responses in vivo. Inhibitor of tyrosine phosphorylation (tyrosine kinase inhibitor), of dihydroorotate dehydrogenase, an enzyme for de novo pyrimidine synthesis, of TNF-dependent NF-κB activation, and of COX-2. The physiological activity of leflunomide is attributed mainly to its metabolite A77 1726 (Prod. No. ALX-430-096).
Product Specific Literature References
Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity-I. Disease modifying action on adjuvant arthritis of the rat: R.R. Bartlett & R. Schleyerbach; Int. J. Immunopharmacol. 7, 7 (1985) Abstract
Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection: R.R. Bartlett, et al.; Agents Actions 32, 10 (1991) Abstract
Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide: T. Mattar, et al.; FEBS Lett. 334, 161 (1993) Abstract
Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide: X. Xu, et al.; J. Biol. Chem. 270, 12398 (1995) Abstract; Full Text
Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide: T.R. Brazelton & R.E. Morris; Curr. Opin. Immunol. 8, 710 (1996) Abstract
The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase: J.P. Davis, et al.; Biochemistry 35, 1270 (1996) Abstract
Regulation of B cell function by the immunosuppressive agent leflunomide: K.F. Siemasko, et al.; Transplantation 61, 635 (1996) Abstract
Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation: X. Xu, et al.; Biochem. Pharmacol. 52, 527 (1996) Abstract
Potencies of leflunomide and HR325 as inhibitors of prostaglandin endoperoxide H synthase-1 and -2: comparison with nonsteroidal anti- inflammatory drugs: A.P. Curnock, et al.; J. Pharmacol. Exp. Ther. 282, 339 (1997) Abstract
In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice: X. Xu, et al.; J. Immunol. 159, 167 (1997) Abstract
Leflunomide, a novel immunomodulating agent, prevents the development of allergic sensitization in an animal model of allergic asthma: E. Eber, et al.; Clin. Exp. Allergy 28, 376 (1998) Abstract
Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives: W. Knecht & M. Löffler; Biochem. Pharmacol. 56, 1259 (1998) Abstract
Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production: K.F. Siemasko, et al.; J. Immunol. 160, 1581 (1998) Abstract
In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression: A.S. Chong, et al.; Transplantation 68, 100 (1999) Abstract
Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF- dependent nuclear factor-kappa B activation and gene expression: S.K. Manna and B.B. Aggarwal; J. Immunol. 162, 2095 (1999) Abstract
A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate- sensitive manner: L.C. Hamilton, et al.; Br. J. Pharmacol. 127, 1589 (1999) Abstract
Leflunomide: mode of action in the treatment of rheumatoid arthritis: F.C. Breedveld & J.M. Dayer; Ann. Rheum. Dis. 59, 841 (2000) Abstract
General Literature References
Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis: M.M. Goldenberg; Clin. Ther. 21, 1837 (1999), (Review) Abstract
Leflunomide, mycophenolic acid and matrix metalloproteinase inhibitors: D.E. Furst; Rheumatology (Oxford) 38 Suppl 2, 14 (1999), (Review) Abstract
Leflunomide and methotrexate: R.F. Laan, et al.; Curr. Opin. Rheumatol. 13, 159 (2001), (Review) Abstract
Experiences with leflunomide in solid organ transplantation: J.W. Williams, et al.; Transplantation 73, 358 (2002), (Review) Abstract
Further Categories Containing This Product:
NF-kB Pathway Inhibitors • Tyrosine Kinase Inhibitors • COX Inhibitors
 
 
APO-54N-035 Revised 10-Oct-08
MDA5 (human) (IntraCellular) Detection Set [For ELISA Application]
Add to Clipboard
SYNONYMS Melanoma Differentiation-associated Gene 5 (human) (IntraCellular) Detection Set [For ELISA Application]
Helicard (human) (IntraCellular) Detection Set [For ELISA Application]
PRODUCT LINE DNA Regulation / Transcription
PRODUCT CATEGORY RNA Helicases / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
APO-54N-035-KI01   1 Set 630.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Human
SENSITIVITY: 0.4ng/ml (range 0 to 32ng/ml).
QUANTITY: For 5x96 wells.
KIT/SET CONTAINS: 1 vial Standard (lyophilized) (STD).
1 vial Coating Antibody (COAT).
1 vial Detection Antibody (DET).
APPLICATION: For the quantitative determination of human MDA5 in cell extracts.
SHIPPING: SHIPPED ON BLUE ICE
SHORT TERM STORAGE: +4°C
LONG TERM STORAGE: -20°C
HANDLING: Avoid freeze/thaw cycles.
Product Description

This intracellular Detection Set is for measuring protein levels in cell lysates.  It allows to quantitatively determine:
a. Levels of MDA5
b. Interferon response since MDA5 is an interferon inducible gene
b. Virus infection response
General Information
The innate immune response to viruses is initiated upon detection of viral RNA generated during the life cycle of most viruses [1]. Recognition of the viral RNA is mediated by either the two cytoplasmic RNA helicases Retinoic acid Inducible Gene-1 (RIG-I ; Ddx58) and Melanoma Differentiation Associated gene 5 (MDA5 / Helicard; Ifih1) [2] or by Toll-like Receptor 3 (TLR3) located to an endosomal-like compartment [3]. RIG-I and MDA5 belongs to the family of RIG-I like receptor (RLR) together with the protein LGP2 whose function is still elusive [4, 5]. Upon binding to RNA, RIG-I or MDA5 binds a new mediator named Cardif, MAVS (mitochondrial antiviral signalling), IPS-1 (interferon-β promoter stimulator 1) or VISA (virus-induced signalling adapter) [6, 7]. Cardif/ MAVS/ IPS-1/ VISA then interacts with several TRAFs molecules, leading to the activation of regulatory kinases, such as TBK1, IKKε , and the IKKα/β/γ complex. These kinases activate respective transcription factors, IRF-3, IRF-7, and NF-κB that participate in the activation of IFN and other inflammatory cytokine genes. RIG-I is activated by dsRNA and 5′-ppp RNA while only poly I: C acts as a chemical agonist for MDA5. The physiological agonist of MDA5 has still to be discovered. Mda-5 is an early response gene inducible by IFN and tumor necrosis factor-α, responding predominantly to IFN-β [8].
BACKGROUND/TECHNICAL INFORMATION Swiss-Prot link Q9BYX4: MDA5 (human)
MANUFACTURER Manufactured by Apotech Corporation.
General Literature References
[8] mda-5: An interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties: D.C. Kang, et al.; PNAS 99, 637 (2002) Abstract; Full Text
[6] Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus: E. Meylan, et al.; Nature 437, 1167 (2005) Abstract
[7] IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction: T. Kawai, et al.; Nat. Immunol. 6, 981 (2005) Abstract
[1] Recognition of viruses by innate immunity: O. Takeuchi & S. Akira; Immunol. Rev. 220, 214 (2007) Abstract
[4] Cytoplasmic recognition of RNA: M. Yoneyama, et al.; Adv. Drug Deliv. Rev. 60, 841 (2008) Abstract
[5] Loss of DExD/H box RNA helicase LGP2 manifests disparate antiviral responses: T. Venkataraman, et al.; J. Immunol. 178, 6444 (2007) Abstract
[2] MDA5/RIG-I and virus recognition: O. Takeuchi & S. Akira; Curr. Opin. Immunol. 20, 17 (2008) Abstract
[3] TLR3: Interferon induction by double-stranded RNA including poly(I:C): M. Matsumoto & T. Seya; Adv. Drug Deliv. Rev. 60, 805 (2008)
Related Products
Further Categories Containing This Product:
NF-kB Pathway Other Products • Antiviral Signalling / Related Products • Caspase Recruitment Domain [CARD] Proteins / Related Products • Interferons & Interferon Receptors Other Products • ELISA Sets
 
 
APO-54N-039 Revised 10-Oct-08 New product
MDA5 (human) (IntraCellular) ELISA Kit
Add to Clipboard
SYNONYMS Melanoma Differentiation-associated Gene 5 (human) (IntraCellular) ELISA Kit
Helicard (human) (IntraCellular) ELISA Kit
PRODUCT LINE DNA Regulation / Transcription
PRODUCT CATEGORY RNA Helicases / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
APO-54N-039-KI01   1 Kit 630.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Human
SENSITIVITY: 0.4ng/ml (range 0.5 to 32ng/ml).
QUANTITY: For 96 wells (~80 tests).
APPLICATION: For the quantitative determination of human MDA5 in cell extracts.
SHIPPING: SHIPPED ON BLUE ICE
SHORT TERM STORAGE: +4°C
LONG TERM STORAGE: -20°C
HANDLING: Avoid freeze/thaw cycles.
General Information
MANUFACTURER Manufactured by Apotech Corporation.
Related Products
Further Categories Containing This Product:
NF-kB Pathway Other Products • Antiviral Signalling / Related Products • Caspase Recruitment Domain [CARD] Proteins / Related Products • Interferons & Interferon Receptors Other Products • ELISA & EIA Kits
 
 
ALX-260-092 Revised 05-Jun-08
MG-132
Add to Clipboard
SYNONYMS Z-LLL-CHO
Z-Leu-Leu-Leu-CHO
PRODUCT LINE Ubiquitin & Proteasome
PRODUCT CATEGORY Proteasome / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-260-092-M001   1 mg 25.00 USD Add To Cart
ALX-260-092-M005   5 mg 60.00 USD Add To Cart
Product Specification
SEQUENCE: Z-Leu-Leu-Leu-CHO
FORMULA: C26H41N3O5
MW: 475.6
CAS NUMBER: 133407-82-6
PURITY: ≥95% (HPLC)
APPEARANCE: White to off-white powder.
SOLUBILITY: Soluble in DMSO.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
IDENTITY: Identity determined by MS.
Product Description
Potent, reversible and cell permeable proteasome inhibitor. Inhibits NF-κB activation.
Product Specific Literature References
Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules: K.L. Rock, et al.; Cell 78, 761 (1994) Abstract
Multiple proteolytic systems, including the proteasome, contribute to CFTR processing: T.J. Jensen, et al.; Cell 83, 129 (1995) Abstract
The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression: M.A. Read, et al.; Immunity 2, 493 (1995) Abstract
Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae: D.H. Lee and A.L. Goldberg; J. Biol. Chem. 271, 27280 (1996) Abstract; Full Text
The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol: E.J. Wiertz, et al.; Cell 84, 769 (1996) Abstract
Proteasome inhibitors activate stress kinases and induce Hsp72. Diverse effects on apoptosis: A.B. Meriin, et al.; J. Biol. Chem. 273, 6373 (1998) Abstract; Full Text
Role of proteasomal degradation in the cell cycle-dependent regulation of DNA topoisomerase IIalpha expression: L. Salmena, et al.; Biochem. Pharmacol. 61, 795 (2001) Abstract
Further Categories Containing This Product:
NF-kB Pathway Inhibitors
 
 
ALX-804-137 Revised 07-Dec-05
Monoclonal Antibody to A20 (human) (8E8.38)
Add to Clipboard
PRODUCT LINE Inflammation
PRODUCT CATEGORY TLRs Other Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-804-137-C050   50 µg 360.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Human
CLONE: 8E8.38
ISOTYPE: Mouse IgG1
FORMULATION: Liquid. In PBS containing 0.02% sodium azide.
IMMUNOGEN: Zinc finger domain corresponding to aa 375-537 of human A20.
SPECIFICITY: Recognizes human A20.
APPLICATION: Western Blot (1:1'000)
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
USE/STABILITY: Stable for at least 1 year after receipt when stored as recommended.
HANDLING: Avoid freeze/thaw cycles.
Product Images
Please click on thumbnails to enlarge.
Product Description
A20 is a zinc finger protein that renders cells resistant to apoptosis. A20-deficient mice develop severe inflammation and are hyper-responsive to LPS. S.M. O'Reilly & P.N. Moynagh have shown that full length A20 inhibits activation of NF-kB and AP-1 by TLR4 [1].  A20 associates with A20-binding inhibitor of NF-kB (ABIN)-1 and -2 [2-4], which interfere with NF-kB activation upstream of the IKK complex.
Product Specific Literature References
A20 inhibits NF-kappa B activation downstream of multiple Map3 kinases and interacts with the I kappa B signalosome: F.S. Zetoune, et al.; Cytokine 15, 282 (2001) Abstract
General Information
MANUFACTURER Manufactured by Apotech Corporation.
General Literature References
[1] Regulation of Toll-like receptor 4 signalling by A20 zinc finger protein: S.M. O'Reilly and P.N. Moynagh; Biochem. Biophys. Res. Commun. 3303, 586 (2003) Abstract
[2] The zinc finger protein A20 inhibits TNF-induced NF-kappaB-dependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-kappaB-inhibiting protein ABIN: K. Heyninck, et al.; J. Cell Biol. 145, 1471 (1999) Abstract; Full Text
[3] Identification of a novel A20-binding inhibitor of nuclear factor-kappa B activation termed ABIN-2: S. Van Huffel, et al.; J Biol Chem 276, 30216 (2001) Abstract; Full Text
[4] Structure-function analysis of the A20-binding inhibitor of NF-kappa B activation, ABIN-1: K. Heyninck, et al.; FEBS Lett. 536, 135 (2003) Abstract
Further Categories Containing This Product:
NF-kB Pathway Other Products • Monoclonal Antibodies • Cell Death / Apoptosis / Autophagy Other Products
 
 
ALX-804-108 Revised 18-Sep-07
Monoclonal Antibody to Ah Receptor Nuclear Translocator (2B10)
Add to Clipboard
SYNONYMS anti-ARNT MAb (2B10)
anti-HIF-1β MAb (2B10)
anti-Hypoxia-inducible Factor 1β MAb (2B10)
PRODUCT LINE DNA Regulation / Transcription
PRODUCT CATEGORY Aryl Hydrocarbon Receptor / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-804-108-R100   100 µl 379.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Human
Mouse
Monkey
CLONE: 2B10
ISOTYPE: Mouse IgG1
CONCENTRATION: 1mg/ml
FORMULATION: Liquid. In PBS containing 1mg/ml BSA and 0.05% sodium azide.
IMMUNOGEN: Synthetic peptide corresponding to aa 771-789 (N771SYNNEEFPDLTMFPPFSE789) of human ARNT (Ah receptor nuclear translocator).
SPECIFICITY: Recognizes human, mouse and monkey ARNT. Detects a band of ~87kDa by Western blot.
APPLICATION: Immunocytochemistry (1:1'000)
Immunoprecipitation
Western Blot (1:4'000)
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
HANDLING: Avoid freeze/thaw cycles.
Product Specific Literature References
Physiochemical and immunocytochemical analysis of the aryl hydrocarbon receptor translocator: Characterization of two monoclonal antibodies to the ARNT: N.G. Hord & G. Perdew; Mol. Pharmacol. 46, 618 (1994) Abstract
Oxygen tension modulates beta-globin switching in embryoid bodies: S. Bichet, et al.; FASEB J. 13, 285 (1999) Abstract; Full Text
Induction and nuclear translocation of hypoxia-inducible factor-1 (HIF-1): heterodimerization with ARNT is not necessary for nuclear accumulation of HIF-1alpha: D. Chilov, et al.; J. Cell Sci. 112, 1203 (1999) Abstract; Full Text
Protein kinase C modulates aryl hydrocarbon receptor nuclear translocator protein-mediated transactivation potential in a dimer context: W.P. Long, et al.; J. Biol. Chem. 274, 12391 (1999) Abstract; Full Text
DNA methylation represses the expression of the human erythropoietin gene by two different mechanisms: H. Yin and K.L. Blanchard; Blood 95, 111 (2000) Abstract; Full Text
A new HIF-1 alpha variant in